PD-L1 was chosen because it is the direct target of atezolizumab, while PD1 was chosen because it is a PD-L1 direct target and because interesting literature data converge on its role as a modulator of the lineage fate commitment and function of myeloid cells generated from tumor-driven emergency myelopoiesis [12]. Here, PDCD1 is linked to neoplasm.